Avenova Spray was Stablecoin Development’s largest product and service line in fiscal 2024, bringing in $8.67M of $9.78M (89%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Product | — | — | — | — | |||||
| Avenova Product | — | — | — | — | |||||
| Avenova Spray | $8.57M | $7.65M | $7.81M | $8.67M | |||||
| Kn95 Masks | — | — | — | — | |||||
| Dermadoctor | $649.00K | $4.16M | — | — | |||||
| Other Products | $598.00K | $1.59M | $1.27M | $1.07M | |||||
| Neutrophase | $368.00K | $976.00K | $1.38M | — | |||||
| Product & Service, Other | $24.00K | $30.00K | — | $34.00K | |||||
| Total | $10.20M | $14.40M | $10.46M | $9.78M |
Stablecoin Development brought in $9.78M from its three product and service lines in fiscal 2024, the year ended December 31, 2024. Stablecoin Development regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $10.46M. Avenova Spray was the largest at $8.67M (88.7%), ahead of Other Products at $1.07M (11.0%) and Product & Service, Other at $34.00K (0.3%).
Compared with fiscal 2023, Avenova Spray grew 11.1% to $8.67M, while Other Products fell 15.6% to $1.07M.
Stablecoin Development stopped reporting Dermadoctor ($4.16M in fiscal 2022) and Neutrophase ($1.38M in fiscal 2023) as separate lines.
Previously Reported was Stablecoin Development’s largest revenue line in fiscal 2021, bringing in $8.40M of $10.18M (82%).
| Revision of Prior Period | FY 2021 |
|---|---|
| Previously Reported | $8.40M |
| Revision Of Prior Period, Change In Accounting Principle, Adjustment | $1.78M |
| Total | $10.18M |
Stablecoin Development brought in $10.18M from its two revenue lines in fiscal 2021, the year ended December 31, 2021. Previously Reported was the largest at $8.40M (82.5%), ahead of Revision Of Prior Period, Change In Accounting Principle, Adjustment at $1.78M (17.5%).
Optical & Wound Care was Stablecoin Development’s largest segment in fiscal 2022, bringing in $10.24M of $14.40M (71%).
| Segment | FY 2012 | FY 2013 | FY 2014 | FY 2021 | FY 2022 |
|---|---|---|---|---|---|
| Optical & Wound Care | $9.56M | $10.24M | |||
| Dermatology | — | — | |||
| Skin Care | $649.00K | $4.17M | |||
| Other Rd | — | — | |||
| Wound Care | — | — | |||
| Ophthalmology | — | — | |||
| Other Segments | — | — | |||
| Total | $10.20M | $14.40M |
Stablecoin Development brought in $14.40M from its two segments in fiscal 2022, the year ended December 31, 2022. That was up 41.2% from $10.20M in fiscal 2021. Optical & Wound Care was the largest at $10.24M (71.1%), ahead of Skin Care at $4.17M (28.9%).
Compared with fiscal 2021, Skin Care grew 541.8% to $4.17M and Optical & Wound Care grew 7.2% to $10.24M.
Stablecoin Development (SDEV) reports its revenue by product and service, by revision of prior period and by segment. In fiscal 2024, Avenova Spray was its largest product and service line, bringing in $8.67M (88.7% of the total), followed by Other Products at $1.07M (11.0%).
Avenova Spray was Stablecoin Development's largest product and service line in fiscal 2024, bringing in $8.67M, or 88.7% of the $9.78M total across its three product and service lines.
Previously Reported was Stablecoin Development's largest revenue line in fiscal 2021, bringing in $8.40M, or 82.5% of the $10.18M total across its two revenue lines.
Optical & Wound Care was Stablecoin Development's largest segment in fiscal 2022, bringing in $10.24M, or 71.1% of the $14.40M total across its two segments.
Skin Care grew faster than Optical & Wound Care in fiscal 2022, up 541.8% from $649.00K to $4.17M. Optical & Wound Care grew 7.2% to $10.24M.
Every figure comes from Stablecoin Development's annual financial filings, as reported. Each line keeps the name Stablecoin Development gives it, and years follow its fiscal calendar.
Stablecoin Development's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.